1. Home
  2. IVA vs CPHC Comparison

IVA vs CPHC Comparison

Compare IVA & CPHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IVA
  • CPHC
  • Stock Information
  • Founded
  • IVA 2011
  • CPHC 1994
  • Country
  • IVA France
  • CPHC United States
  • Employees
  • IVA N/A
  • CPHC N/A
  • Industry
  • IVA Biotechnology: Pharmaceutical Preparations
  • CPHC Services-Misc. Amusement & Recreation
  • Sector
  • IVA Health Care
  • CPHC Consumer Discretionary
  • Exchange
  • IVA Nasdaq
  • CPHC Nasdaq
  • Market Cap
  • IVA 117.3M
  • CPHC 94.6M
  • IPO Year
  • IVA 2020
  • CPHC 1994
  • Fundamental
  • Price
  • IVA $2.35
  • CPHC $20.89
  • Analyst Decision
  • IVA Strong Buy
  • CPHC
  • Analyst Count
  • IVA 4
  • CPHC 0
  • Target Price
  • IVA $13.25
  • CPHC N/A
  • AVG Volume (30 Days)
  • IVA 9.3K
  • CPHC 2.5K
  • Earning Date
  • IVA 09-25-2024
  • CPHC 11-07-2024
  • Dividend Yield
  • IVA N/A
  • CPHC 1.34%
  • EPS Growth
  • IVA N/A
  • CPHC N/A
  • EPS
  • IVA N/A
  • CPHC 0.94
  • Revenue
  • IVA $20,652,523.00
  • CPHC $62,111,814.00
  • Revenue This Year
  • IVA N/A
  • CPHC N/A
  • Revenue Next Year
  • IVA $361.78
  • CPHC N/A
  • P/E Ratio
  • IVA N/A
  • CPHC $22.19
  • Revenue Growth
  • IVA N/A
  • CPHC 0.13
  • 52 Week Low
  • IVA $1.53
  • CPHC $17.10
  • 52 Week High
  • IVA $4.75
  • CPHC $30.25
  • Technical
  • Relative Strength Index (RSI)
  • IVA 36.64
  • CPHC 52.41
  • Support Level
  • IVA $2.22
  • CPHC $19.92
  • Resistance Level
  • IVA $2.39
  • CPHC $20.95
  • Average True Range (ATR)
  • IVA 0.10
  • CPHC 1.04
  • MACD
  • IVA -0.03
  • CPHC -0.08
  • Stochastic Oscillator
  • IVA 24.76
  • CPHC 39.18

About IVA Inventiva S.A. American Depository Shares

Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Majority of the group's revenue is derived from its research partnerships with AbbVie and BI.

About CPHC Canterbury Park Holding Corporation 'New'

Canterbury Park Holding Corp is in the business of pari-mutuel wagering on horse races and unbanked card games at its canterbury park racetrack and card casino facility in Minnesota. The company has four operating segments. The horse racing segment represents pari-mutuel wagering operations on simulcast and lives horse races; the Casino segment represents unbanked card operations; the food and beverage segment includes concessions, catering, and events services provided at the Racetrack; and the development segment represents its real estate development operations. The firm generates a majority of its revenue from the Casino segment.

Share on Social Networks: